Beam Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
Get Alerts BEAM Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:30 a.m. ET. The conference is being held virtually from June 2-4, 2020.
The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit www.beamtx.com.
Contacts:
Investors:Alicia Davis, THRUST Strategic Communications[email protected]
Media:Dan Budwick1AB[email protected]
Source: Beam TherapeuticsSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HII’s Newport News Shipbuilding Completes Successful Acceptance Sea Trials of John F. Kennedy (CVN 79)
- Bell Medical Announces Partnership with Feellife
- Dogecoin Price Prediction: $0.15 Bull Case Would More Than Double DOGE as AlphaPepe $1 Roadmap Talk Targets Bigger Upside
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share